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Abstract
Background: Intracranial stenosis is the most common cause of stroke among Asians. It has a
poor prognosis with a high rate of recurrence. No effective medical or surgical treatment modality
has been developed for the treatment of stroke due to intracranial stenosis. We aim to identify risk
factors and biomarkers for intracranial stenosis and to develop techniques such as use of
transcranial doppler to help diagnose intracranial stenosis in a cost-effective manner.
Methods/Design: The Karachi Intracranial Stenosis Study (KISS) is a prospective, observational,
case-control study to describe the clinical features and determine the risk factors of patients with
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stroke due to intracranial stenosis and compare them to those with stroke due to other etiologies
as well as to unaffected individuals. We plan to recruit 200 patients with stroke due to intracranial
stenosis and two control groups each of 150 matched individuals. The first set of controls will
include patients with ischemic stroke that is due to other atherosclerotic mechanisms specifically
lacunar and cardioembolic strokes. The second group will consist of stroke free individuals.
Standardized interviews will be conducted to determine demographic, medical, social, and
behavioral variables along with baseline medications. Mandatory procedures for inclusion in the
study are clinical confirmation of stroke by a healthcare professional within 72 hours of onset, 12
lead electrocardiogram, and neuroimaging. In addition, lipid profile, serum glucose, creatinine and
HbA1C  will be measured in all participants. Ancillary tests will include carotid ultrasound,
transcranial doppler and magnetic resonance or computed tomography angiogram to rule out
concurrent carotid disease. Echocardiogram and other additional investigations will be performed
at these centers at the discretion of the regional physicians.
Discussion: The results of this study will help inform locally relevant clinical guidelines and
effective public health and individual interventions.
Background
Stroke is the third leading cause of death worldwide and
about two-thirds of all strokes occur in developing coun-
tries. [1] Intracranial stenosis (ICS) due to atherosclerosis
of the large arteries is the most common cause of stroke
among Asians as well as African and Hispanic popula-
tions.[2-4] In contrast, Caucasians suffer from stroke most
commonly due to extracranial large artery disease, partic-
ularly involving the carotid bifurcation. [3] Asians make
up approximately half of the world's population and
therefore ICS is probably the most common cause of
stroke in the world.
Current therapeutic strategies for ICS
The prognosis of stroke due to intracranial stenosis is poor
with a recurrence rate of 38% at two years.[5] The warfarin
aspirin intracranial stenosis (WASID) trial showed that
despite anticoagulation with warfarin or use of high dose
aspirin, the rate of re-emergent stroke is high in the territory
of the affected artery.[6] The WASID trail further revealed
that the use of warfarin with INR maintained at 2–3 was
not superior to high dose aspirin at preventing the primary
end point of stroke due to intracranial atherosclerosis.[6]
Warfarin did reduce the risk of the primary end point in
patients with basilar artery stenosis. However, there was no
reduction in stroke in the basilar artery territory or benefit
for vertebral artery stenosis or posterior circulation disease
in general.[7] Cilostazol, a phosphodiesterase inhibitor
that reduces re-stenosis rate after coronary angioplasty and
stenting, has recently been reported in an Asian study to sig-
nificantly reduce the risk of re-stenosis in patients with
intracranial stroke.[8] While this study is promising it lacks
sufficient follow up because these lesions are dynamic and
exhibit spontaneous regression.
Surgical interventions have also been studied without
favourable outcomes. The EC/IC bypass study was an
extensive, multi-centre, randomized trial that showed that
anastomosis of the superficial temporal artery to the mid-
dle cerebral artery for the prevention of recurrence of
stroke actually leads to poorer functional outcomes in
treated patients.[9,10]Presently, patients who fail to ben-
efit from medical therapy are considered candidates for
stent placement in the intracranial vessels. A multi-center,
nonrandomized, prospective feasibility study evaluated
the NEUROLINK system for treatment of vertebral or
intracranial artery stenosis. This study showed that the re-
stenosis rate among participants was 35 percent.[11] This
high rate is a cause for concern but this study and other
such studies using drug eluting stents do show the techni-
cal feasibility of such procedures.[12] Presently, such
interventions for intracranial stenosis are considered
experimental.[13] In addition, their cost limits their wide-
spread use in resource poor settings.
Current Biochemical Associations of Intracranial Stenosis
Stroke due to intracranial atherosclerosis is associated
with atherosclerotic plaque formation in other parts of the
body particularly the aorta.[14] There is 50% likelihood
of coronary artery disease in patients with intracranial ste-
nosis.[15] In addition, there is evidence that inflamma-
tion is an important determinant of atherosclerosis and
stroke.[16] Its contribution seems to be higher especially
in intracranial stroke. The inflammatory mechanisms at
play include endothelial dysfunction, leukocyte migra-
tion, extra-cellular matrix degradation, and platelet activa-
tion.[17] Hence, there is increasing interest in
inflammatory biomarkers of intracranial stenosis that
may help determine its pathophysiology and provide cli-
nicians with methods to quantify inflammation, to pre-
dict the risk of recurrent atherothrombosis and its clinical
sequelae and to develop optimal therapeutic strate-
gies.[18,19] C Reactive Protein (CRP) is a viable inflam-
matory biomarker which is activated by cytokines and hasBMC Neurology 2009, 9:31 http://www.biomedcentral.com/1471-2377/9/31
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a pivotal role in the development and progression of
atherosclerosis by induction of endothelial dysfunction
[20], promotion of foam cell formation [21], inhibitions
of endothelial progenitor cell survival and differentiation
[22] and activation of complement in atherosclerotic
plaque intima.[23] Increased CRP levels strongly predict
risk for new ischemic events in primary symptomatic
intracranial large-artery stroke.[24] Acute increases in the
levels of Von Willibrandt factor (vWF) may be another
indicator of stroke as its levels in the serum may reflect
endothelial cell activation which is a necessary step in the
initiation of inflammation.[25] The expression of matrix
metalloproteinases (Mumps) is highly increased in
atherosclerotic plaques [26] and these include MMP-1,
MMP-2, and MMP-9. They are believed to play a role in
the degradation of the fibrous cap of the atheroma leading
to its instability.
Insulin dependent diabetes mellitus and metabolic syn-
drome are independently associated with a greater likeli-
hood of intracranial large-artery atherosclerosis and
diabetic patients have a significantly higher number of
diseased vessels compared to disease free individu-
als.[27,28] Dyslipidemia, high lipoprotein A levels [29],
smoking and decreased level of endostatin (an angiogen-
esis promoter) are all associated with intracranial steno-
sis.[30]
Gaps in Knowledge
Intracranial stenosis is a common cause of disabling
stroke in Asians. However, most studies used to establish
its pathogenesis and risk factors have been conducted in
North America or Europe where the population is
unlikely to be representative of Asians. Furthermore, the
prevention and control of stroke due to intracranial sten-
osis is particularly challenging as effective treatment
options have not been established.
Objectives of the Karachi Intracranial Stenosis Study 
(KISS)
The objectives of this study are to establish risk factors and
to identify clinical, biochemical and radiological predic-
tors of intracranial stenosis in South Asia. This study will
also evaluate the validity of transcranial doppler as a diag-
nostic modality for stroke due to intracranial stenosis in
this population.[8,31]
Methods/Design
Study Design
An observational, prospective case-control study is being
conducted in order to describe the clinical presentation
and hemodynamic parameters of patients who present
with stroke due to intracranial vascular stenosis. Potential
risk factors of intracranial stenosis will be compared with
two groups of controls one of which comprises of patients
with stroke due to non-ICS etiologies and the other com-
prises of patients without clinical evidence of stroke.
Study Site
Stroke patients presenting to three urban tertiary care hos-
pitals in Karachi are included in the study.
Sample size
The targeted sample size of the study is 500 participants
including 200 cases with stroke due to ICS (Group A), 150
controls with stroke due to non-ICS etiologies (Group B)
and 150 stroke-free age and gender matched controls
(Group C). This sample size gives the study 95% confi-
dence and 80% power to detect any risk factors of stroke
due to ICS that have a community prevalence of at least
20% and a 1.80 times higher odds in ICS patients as com-
pared to stroke-free controls.
Study Cases
Men and women aged 18 years or older, who present to
the emergency rooms of participating hospitals and are
subsequently admitted under the medicine, neurology or
intensive care service with a diagnosis of stroke due
atherosclerosis, are enrolled in this study by trained med-
ical research officers. The qualifying event for enrollment
in this group is sudden neurological deficit consistent
with the World Health Organization criteria for stroke.
According to this criteria, stroke is clinically defined by
rapidly developing signs of focal (or global) disturbance
of cerebral function lasting greater than twenty-four hours
(unless interrupted by surgery or death), with no apparent
nonvascular cause. This definition excludes patients with
transient cerebral ischemia or stroke events in cases of
blood disease or brain tumours.[32] Secondary strokes
caused by trauma or iatrogenesis are also excluded.[33]
Furthermore, the diagnosis of stroke must be supported
by evidence of stroke on magnetic resonance imaging
(MRI) or non-contrast computed tomography (CT) of the
brain. Finally, in order to determine that the stroke was
due to intracranial stenosis, magnetic resonance angiogra-
phy (MRA) is used.
Inclusion Criteria for Cases
All patients presenting to the study center are eligible for
inclusion in the study if they fulfill the following require-
ments:
1. Development of sudden onset neurological deficit
respecting a vascular territory with sustained deficit at
24 hours verified by a healthcare professional within
72 hours after onset. Onset is defined by when the
patient was last seen normal.
2. Evidence of stroke on MRI or non contrast CT scan
confirmation of intracranial stenosis on MRA.BMC Neurology 2009, 9:31 http://www.biomedcentral.com/1471-2377/9/31
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3. Age greater than or equal to 18 years.
4. Modified Rankin Score less than two prior to the
presenting stroke.
Exclusion Criteria for Cases
Patients are excluded from the study if they meet any of
the following criteria:
1. Hemorrhagic stroke or stroke due to non-athero-
sclerotic etiology, for example, Moya Moya, carotid or
vertebral dissection, venous stroke, concomitant
hypercoaguable state, iatrogenic stroke or stroke due
to trauma.
2. Baseline mRS of three or more prior to the present-
ing event.
3. Life expectancy is less than six months.
4. Alcohol or drug dependence as determined by the
medical research officer.
5. Inability to consent due to disability and non-avail-
ability of a valid surrogate respondent. A valid surro-
gate respondent is defined as a spouse, a first degree
relative living in the same house or an attendant self
identified as aware of the patient's medical history,
habits and behaviors.
Controls
Two groups of controls are planned. Patients presenting
with ischemic stroke due to small vessel disease or cardio-
embolism according to the TOAST criteria comprise the
first group.[34,35] The second control group includes par-
ticipants who have never suffered a clinical cerebrovascu-
lar event (stroke or transient ischemic attacks) as
determined by a locally validated Questionnaire for Veri-
fying Stroke Free Status (QVSS).[36]
Selection Criteria for Stroke-free Controls
In order to minimize potential selection bias, controls are
selected in the following order of priority.
1. The patients' spouses or other non-blood related
relatives without any neurovascular event.
2. Non first degree relatives visiting the patient.
3. Patients from out-patient departments undergoing
routine health evaluation.
4. Patients from out-patient departments with minor
complaints for example, refractive errors, cataracts and
minor ear, nose and throat complaints.
5. Patients from surgical day care departments under-
going minor elective surgery for example, hernia
repair, hemorrhoids, etc.
Matching Criteria for Stroke-free Controls
Cases and controls are matched according to gender and
age (frequency matched).
Exclusion Criteria for Stroke-free Controls
Individuals with any of the following conditions are
excluded from this group:
1. Stroke or TIA phenotype or undefined prior neuro-
logic event.
2. History of myocardial infarction or a history of cor-
onary artery bypass and graft surgery.
3. Inability to provide consent.
4. Pregnancy.
5. Chronic conditions with major organ dysfunction
such as malignancy, chronic renal failure, tuberculosis
or chronic hepatitis.
Study Procedures
Patients with suspected intra-cranial large artery ischemic
stroke admitted to the participating hospitals are evalu-
ated by physicians according to current standards for care.
The evaluation includes history taking, complete physical
examination, radiology including CT or MRI of the brain
and MRA of the head as well as routine blood tests for
evaluation of stroke patients. A standardized, structured
interview is conducted and investigation results are
recorded. Demographic, medical, social, and behavioral
variables are determined along with baseline medications.
Anthropometry is performed using standardized equip-
ment calibrated on a daily basis. Mandatory tests include
12 lead echocardiogram (EKG), neuroimaging (CT or
MRI) and blood tests including lipid profile, serum glu-
cose and HBA1C measurements. Ancillary vascular imag-
ing includes carotid ultrasound and MR or CT angiogram
to rule out concurrent carotid disease. Additional testing
is at the discretion of the treating physician at these cent-
ers. Controls undergo the same standard interview and
biochemical investigations.
All clinical data, biological samples and radiological
images are sent to the central study site where a cerebrov-
ascular neurologist reviews the data and subtypes the
strokes in all participants according to the TOAST criteria.
A summary of the study procedures is presented in
Figure 1.BMC Neurology 2009, 9:31 http://www.biomedcentral.com/1471-2377/9/31
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Data Collection Instrument
The following data is recorded in the data collection
instrument:
1. Sociodemographic data (age, gender, and ethnicity)
that is later coded for confidentiality and analysis.
2. Hospitalization information for the event and pre-
hospital delays, with functional status prior to event.
3. Risk Factor Information, using internationally
accepted definitions of hypertension [37], diabetes
mellitus [38], smoking status, dyslipidemia [39], ante-
cedent family history of any vascular event, presence
of diabetic nephropathy, carotid stenosis, atrial fibril-
lation, ghutka(oral local tobacco) use, alcohol use and
use of alternative healthcare
4. Anthropometric measurements including height,
weight, waist-hip ratio, leg length, arm span and body
mass index.
5. Electrocardiogram records are archived directly
while all radiologic films are captured as digital
images and archived on a central imaging databank.
6. Procedures carried out during hospital stay includ-
ing use of antiplatelets within 24 hours, smoking ces-
sation counseling, early mobilization, use of
recombinant tissue plasminogen activator, dysphagia
screening and avoidance of aspiration are specifically
recorded. These variables evaluate the basic tenets of
stroke care based on internationally validated
data.[13,40,41]
7. In-hospital complications are noted. These include
neurological complications such as recurrence of
stroke, epileptic seizures and stroke progression; infec-
tions involving respiratory and urinary tracts; and
complications of immobility such as falls, bedsores,
deep vein thrombosis and pulmonary embolism.
Karachi Intracranial Stenosis Study; a summary of the study procedures Figure 1
Karachi Intracranial Stenosis Study; a summary of the study procedures.
Karachi Intracranial Stenosis Study (KISS) 
Multi-centre recruitment 
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Transcranial Doppler
Transcranial Doppler ultrasound will be performed in all
patients with ischemic stroke included in the study. The
sensitivity and specificity of TCD will be evaluated in this
population as a screening test for the presence of hemody-
namically significant intracranial stenosis as identified by
MRA.
Follow Up
The enrolled cases and controls from both groups will be
followed up at one, three and six months through a tele-
phonic assessment. The objectives of the follow-up
include:
1. To determine the development of delayed compli-
cations including but not limited to dementia, depres-
sion, emotionalism, frozen shoulder and post stroke
pain syndrome.
2. To determine functional status using published
scales (Barthel, Modified Rankin Score).
3. To determine if case fatality has taken place. For
those patients who die between the periods of the fol-
low up, a sensitive verbal autopsy shall be per-
formed.[42]
Data Management and Analysis
The data will be entered on Statistical Package for Social
Sciences (SPSS) Version 16 and analyzed using STATA ver-
sion 10. Univariate and multivariate analysis will be used
to determine significance of the results obtained.
Ethical Considerations
The study protocol has been approved by the Ethical
Review Committee of all participating sites. No financial
incentives are provided to any study participant. Written
informed consent and verbal assent is given by all partici-
pants or their surrogate prior to the interview.
Discussion
Intracranial stenosis may be the most common cause of
stroke in the developing world. Pakistan has an exceed-
ingly high prevalence of modifiable risk factors for stroke.
Hypertension afflicts one-third of those over 45 years of
age and one-fifth of those over 15 years.[43] The National
Health Survey of Pakistan revealed that diabetes mellitus
is present in 35% of people older than 45 years.[43] The
overall prevalence of obesity is 28% in women and 22%
in men while the prevalence of tobacco use is 33% in men
and 4.7% in women.[44,45] This data suggests that Paki-
stan is on the cusp of a stroke epidemic as the population
undergoes a demographic shift.[46]It is imperative to
have cost effective and locally relevant solutions as a
response to stroke. Clearly, optimal preventive or thera-
peutic strategies depend upon informed decisions. The
results of this study will serve to bridge gaps in knowledge
of stroke due intracranial stenosis in developing coun-
tries. In addition, this study will evaluate the use of TCD
as an accessible screening tool for intracranial stenosis.
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